Vera Therapeutics, Inc. (NASDAQ:VERA) Director Beth C. Seidenberg Sells 15,000 Shares

Vera Therapeutics, Inc. (NASDAQ:VERA) Director Beth C. Seidenberg sold 15,000 shares of the stock in a transaction on Monday, October 28th. The stock was sold at an average price of $48.03, for a total value of $720,450.00. Following the completion of the sale, the director now owns 131,553 shares in the company, valued at approximately $6,318,490.59. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Vera Therapeutics Price Performance

Shares of VERA stock opened at $43.82 on Friday. Vera Therapeutics, Inc. has a fifty-two week low of $9.68 and a fifty-two week high of $50.78. The firm has a market capitalization of $2.40 billion, a price-to-earnings ratio of -19.83 and a beta of 1.00. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.43 and a current ratio of 21.43. The stock’s 50-day simple moving average is $40.53 and its 200-day simple moving average is $38.90.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). As a group, equities analysts forecast that Vera Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Scotiabank began coverage on Vera Therapeutics in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $60.00 target price on the stock. JPMorgan Chase & Co. increased their price target on Vera Therapeutics from $62.00 to $72.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 3rd. Evercore ISI raised Vera Therapeutics to a “strong-buy” rating in a research report on Monday, September 16th. Cantor Fitzgerald reissued an “overweight” rating and set a $107.00 price target on shares of Vera Therapeutics in a research report on Tuesday, October 1st. Finally, Guggenheim increased their price target on Vera Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research report on Monday, October 28th. One analyst has rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Vera Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $53.56.

Institutional Investors Weigh In On Vera Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of VERA. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Vera Therapeutics by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock worth $86,000 after purchasing an additional 350 shares during the period. Public Employees Retirement Association of Colorado acquired a new position in Vera Therapeutics in the second quarter valued at approximately $135,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Vera Therapeutics in the second quarter valued at approximately $163,000. Ameritas Investment Partners Inc. lifted its holdings in Vera Therapeutics by 20.8% in the first quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock valued at $172,000 after acquiring an additional 688 shares during the period. Finally, Cetera Advisors LLC acquired a new position in Vera Therapeutics in the first quarter valued at approximately $235,000. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.